Physician profile
David M Chaletsky
NPI 1316193055
$19,005.08
in general payments reported to CMS, 2019-2025
34 companies · $2,152 in 2025
The $2,152 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,536 · 2020: $157 · 2021: $2,863 · 2022: $357 · 2023: $2,019 · 2024: $1,922 · 2025: $2,152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,072 · Education: $20.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,071.76 |
| Education | $20.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien LP | $8,560.89 | 2019 | |
| Medtronic, INC. | $2,863.78 | 2021-2024 | Barrx |
| Abbvie INC. | $1,551.72 | 2019-2025 | Rinvoq, Linzess, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,105.70 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $806.97 | 2019-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $651.49 | 2019-2025 | Stelara, Tremfya, Simponi |
| Genzyme Corporation | $516.70 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $451.52 | 2022-2025 | Rebyota, Clenpiq |
| Phathom Pharmaceuticals, INC. | $423.64 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $321.52 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $302.93 | 2021-2023 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $239.72 | 2022-2025 | Dupixent |
| Lilly USA, LLC | $157.21 | 2024-2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $153.74 | 2021-2024 | Linzess |
| Ardelyx, INC. | $114.24 | 2023-2025 | Ibsrela |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $112.13 | 2019 | |
| Pentax of America, INC. | $105.08 | 2023-2024 | C2 Cryoballoon, Pentax Medical, Inspira |
| Pfizer INC. | $82.28 | 2019-2024 | |
| Intercept Pharmaceuticals, INC. | $59.16 | 2019-2024 | Ocaliva |
| Qol Medical, LLC | $57.79 | 2019 | |
| Ucb, INC. | $53.66 | 2019 | |
| Merit Medical Systems INC | $48.33 | 2020 | |
| Evoke Pharma, INC. | $37.98 | 2025 | |
| Gilead Sciences, INC. | $36.31 | 2019-2022 | |
| Braintree Laboratories, INC. | $32.05 | 2023-2025 | Sutab, Suflave |
| Shionogi INC | $27.93 | 2019 | |
| Fujifilm Healthcare Americas Corporation | $23.48 | 2020 | |
| Boston Scientific Corporation | $22.60 | 2024 | Resolution 360 Clip |
| Celltrion USA INC. | $20.70 | 2024 | Zymfentra |
| Nestle Healthcare Nutrition INC. | $17.56 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.14 | 2022 | |
| Shire North American Group INC | $15.30 | 2019 | |
| Merck Sharp & Dohme LLC | $14.83 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$77,759.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Chaletsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.